Management of Alternative Treatment Regimen for EPTB After DILI

Initial Management After DILI

When liver injury occurs, all hepatotoxic drugs should be stopped immediately, and a non-hepatotoxic regimen consisting of streptomycin and ethambutol should be initiated until liver function normalizes, as recommended by the American Thoracic Society 1, 2
Ethambutol should be given at 15-20 mg/kg daily, according to the Centers for Disease Control and Prevention 3

Sequential Reintroduction Protocol

Isoniazid should be reintroduced first, starting at 50 mg/day and increasing to 300 mg/day after 2-3 days if no reaction occurs, as recommended by the American Thoracic Society 1, 2, 4
Rifampicin should be added after 2-3 days of full-dose isoniazid without reaction, starting at 75 mg/day and increasing to 300 mg after 2-3 days, and further increasing to 450 mg (<50 kg) or 600 mg (>50 kg) after another 2-3 days, according to the American Thoracic Society 1, 2, 4
Pyrazinamide should be added last, if needed, starting at 250 mg/day and increasing to 1.0 g after 2-3 days, and then to 1.5 g (<50 kg) or 2.0 g (>50 kg), as recommended by the American Thoracic Society 1, 2

Alternative Regimens Based on Drug Tolerance

If pyrazinamide cannot be tolerated, the alternative regimen of isoniazid, rifampicin, and ethambutol for 2 months, followed by isoniazid and rifampicin for 7 months (total 9 months) should be considered, according to the American Thoracic Society and the Centers for Disease Control and Prevention 1, 2, 4
If isoniazid cannot be tolerated, the alternative regimen of rifampicin, ethambutol, and a fluoroquinolone for 12 months should be considered, as recommended by the Infectious Diseases Society of America 4

Monitoring Protocol During Reintroduction

Liver function tests should be monitored weekly for the first 2 weeks after each drug reintroduction, and then every 2 weeks for the first 2 months, as recommended by the American Thoracic Society and the Infectious Diseases Society of America 2, 4
Patients should be educated about symptoms of hepatotoxicity and instructed to stop medication and seek medical attention if these occur, according to the Infectious Diseases Society of America 5, 6

Special Considerations for EPTB

For EPTB, particularly TB meningitis, treatment duration may need to be extended to 9-12 months even with standard regimens, as recommended by the American Academy of Family Physicians 7
Corticosteroids should be considered for tuberculous pericarditis or meningitis to prevent complications, according to the American Academy of Family Physicians 7

Important Precautions

Concurrent use of other hepatotoxic medications during treatment should be avoided, as recommended by the Infectious Diseases Society of America 6
Patients with pre-existing liver disease require more careful monitoring and are at higher risk for recurrent DILI, according to the Infectious Diseases Society of America 6
Streptomycin should be used with caution in pregnant patients due to risk of congenital deafness, as recommended by the American Academy of Family Physicians 7

Re-initiating Anti-TB Medications After Drug-Induced Liver Injury

Introduction to Re-initiation Protocols

The American Thoracic Society guidelines recommend avoiding the reintroduction of pyrazinamide in patients who had severe initial hepatotoxicity, as pyrazinamide-induced hepatitis occurring late (>1 month after treatment initiation) has a poor prognosis 8

Patient Risk Factors for Recurrent DILI

Patients with a history of INH-associated liver injury should not be offered rifampin-pyrazinamide regimens, according to the Centers for Disease Control and Prevention guidelines 9
The Centers for Disease Control and Prevention also recommend that patients with a history of INH-associated liver injury should not be offered rifampin-pyrazinamide regimens, due to the increased risk of recurrent liver injury 10
Patients at highest risk for recurrence include those with pre-existing liver disease or cirrhosis, chronic alcohol use, hepatitis B or C infection, HIV infection, malnutrition, advanced age, NAT2 slow acetylation genotype, and GSTM1 gene variation, with low pretreatment serum albumin level being a statistically significant predictor of recurrence 11

Alternative Antitubercular Treatment in Pyrazinamide Toxicity

Rationale for Extended Duration

The American Thoracic Society recommends a 9-month treatment duration with rifampicin and isoniazid, supplemented with ethambutol for the initial 2 months, when pyrazinamide is discontinued due to toxicity, as pyrazinamide's sterilizing activity contributes to treatment shortening, with an adjusted odds ratio of 1.6 (95% CI, 1.3–2.1) for cure/complete versus failure/relapse/death when pyrazinamide-susceptible isolates are treated with the drug, in patients with drug-susceptible TB 12

Management of Severe Transaminitis Without Significant Hyperbilirubinemia on Anti-Tubercular Therapy

Immediate Actions

Stop rifampicin, isoniazid, and pyrazinamide immediately if AST/ALT rises to five times the upper limit of normal, regardless of bilirubin levels or symptoms, as recommended by the American Thoracic Society 13
Discontinue all hepatotoxic anti-tubercular drugs when transaminases reach ≥5× upper limit of normal, even if the patient is asymptomatic and bilirubin remains normal, according to the American Thoracic Society 13
If the patient is unwell or has smear-positive sputum within two weeks of starting treatment, initiate streptomycin and ethambutol immediately as bridge therapy until liver function normalizes, as suggested by the American Thoracic Society 13
If the patient is not unwell and has non-infectious tuberculosis, no treatment is required until liver function returns to normal, as recommended by the American Thoracic Society 13

Exclude Other Causes of Hepatotoxicity

Perform virological tests for hepatitis A, B, C, and E, as recommended by the Centers for Disease Control and Prevention 13
Assess alcohol consumption history, as concurrent alcohol use significantly increases hepatotoxicity risk, according to the Centers for Disease Control and Prevention 14

Sequential Drug Reintroduction Protocol

Once transaminases normalize, reintroduce drugs sequentially with daily monitoring of clinical condition and liver function tests, as recommended by the American Thoracic Society 13
Reintroduce isoniazid first, starting at 50 mg/day, and increase to 300 mg/day after 2-3 days if no reaction occurs, as suggested by the American Thoracic Society 13
Add rifampicin second, starting at 75 mg/day, and increase to 300 mg after 2-3 days, and further increase to 450 mg (<50 kg) or 600 mg (>50 kg) after another 2-3 days without reaction, as recommended by the American Thoracic Society 13
Add pyrazinamide last, starting at 250 mg/day, and increase to 1.0 g after 2-3 days, and further increase to 1.5 g (<50 kg) or 2.0 g (>50 kg), as suggested by the American Thoracic Society 13

Alternative Regimens If Drugs Cannot Be Reintroduced

If pyrazinamide is the offending drug, extend treatment to 9 months total with rifampicin and isoniazid, supplemented with ethambutol for the initial 2 months, as recommended by the American Thoracic Society 13

Monitoring During Reintroduction

Check liver function tests (AST/ALT) daily during the reintroduction phase, as recommended by the American Thoracic Society 13
Assess for symptoms of hepatotoxicity daily, including fever, malaise, vomiting, jaundice, or unexplained deterioration, as suggested by the American Thoracic Society 13
Stop the most recently added drug immediately if transaminases rise again or symptoms develop, as recommended by the American Thoracic Society 13

Special Considerations

Patients with pre-existing liver disease require more intensive monitoring, with weekly liver function tests for two weeks, then biweekly for the first two months, as recommended by the Centers for Disease Control and Prevention 13 and the American Thoracic Society 14
Avoid alcohol completely during anti-tuberculosis treatment due to additive hepatotoxicity risk, as recommended by the Centers for Disease Control and Prevention 14

Management of Antituberculosis Therapy Rechallenge After Drug‑Induced Liver Injury

Immediate Management of DILI

Stop all hepatotoxic anti‑TB drugs (isoniazid, rifampicin, pyrazinamide) when serum ALT or AST rises to ≥ 5 × upper‑limit‑of‑normal (ULN) in asymptomatic patients, or ≥ 3 × ULN accompanied by symptoms (jaundice, nausea, vomiting, right‑upper‑quadrant pain), or when bilirubin reaches ≥ 2 × ULN or INR > 1.5. 15
Before restarting therapy, exclude competing causes such as viral hepatitis (A, B, C, E), recent alcohol use, other hepatotoxic medications, and biliary tract disease. 15

Timing of Rechallenge Initiation

Begin sequential re‑introduction of anti‑TB drugs only after transaminases have returned to normal (or are < 2–3 × ULN for patients whose baseline values were already near the upper limit). 16
In patients with an elevated baseline ALT (≥ 1.5 × ULN), wait until ALT falls below 4 × ULN if the baseline was 1.5–3 × ULN, or below 6 × ULN if the baseline was 3–5 × ULN, before starting rechallenge. [16][17]

Absolute Contraindications to Rechallenge

Do not rechallenge if the patient meets Hy’s Law criteria (ALT ≥ 3 × ULN and bilirubin ≥ 2 × ULN).
Rechallenge is also contraindicated in the presence of hepatic decompensation (e.g., ascites, encephalopathy) or hypersensitivity features (rash, fever, eosinophilia, lymphadenopathy). [16][17]
Cirrhosis or advanced liver disease generally precludes rechallenge because of the high risk of further hepatic deterioration. [16][17]

Alternative Regimen When Rifampicin Cannot Be Tolerated

If rifampicin must be omitted, employ a regimen of isoniazid + ethambutol + a fluoroquinolone (levofloxacin or moxifloxacin) for 18–24 months, analogous to a multidrug‑resistant TB (MDR‑TB) protocol. 18

Management of Late Drug‑Induced Liver Injury During Tuberculosis Treatment

Immediate Cessation of Hepatotoxic Antitubercular Drugs

In patients with tuberculosis who develop significant liver injury, all first‑line hepatotoxic agents (isoniazid, rifampicin, pyrazinamide) should be stopped immediately when any of the following laboratory or clinical criteria are met:

Bridge Therapy While Liver Function Recovers

Infectious or acutely ill tuberculosis patients (e.g., sputum smear‑positive) should receive streptomycin plus ethambutol as a temporary bridge regimen until liver enzymes and bilirubin return to normal. 19
Stable, non‑infectious patients may defer antitubercular therapy altogether until hepatic parameters normalize. 19

Criteria for Initiating Drug Re‑introduction

Re‑introduction of antitubercular drugs is permitted only after complete normalization of transaminases and bilirubin. 19

Sequential Re‑introduction Protocol

Isoniazid

Begin with a low dose (≈ 50 mg once daily).
If no adverse reaction after 2–3 days, increase to the full standard dose (≈ 300 mg daily).
Maintain the full dose for an additional 2–3 days before adding the next drug. 19

Rifampicin

Start at a low dose (≈ 75 mg once daily).
If tolerated for 2–3 days, raise to 300 mg daily.
After another 2–3 days without reaction, increase to the weight‑based full dose (≈ 450 mg for patients < 50 kg; ≈ 600 mg for patients ≥ 50 kg).
Continue the full dose for 2–3 days before considering the next agent. 19

Pyrazinamide (only in early‑onset DILI)

If the initial injury was early (< 15 days) and mild, pyrazinamide may be re‑introduced starting at ≈ 250 mg daily, escalating to 1.0 g after 2–3 days, then to the weight‑based full dose (≈ 1.5 g for < 50 kg; ≈ 2.0 g for ≥ 50 kg).
In late‑onset DILI (> 1 month after treatment start), pyrazinamide must NOT be re‑introduced because of a high risk of recurrence and poor prognosis. 19

Monitoring During Re‑introduction

Check transaminases and bilirubin daily after each drug addition.
Observe for hepatic symptoms (fever, malaise, vomiting, jaundice, abdominal pain) each day.
Immediately discontinue the most recently added drug if enzymes rise again or symptoms appear. 19

Alternative Regimens When Pyrazinamide Cannot Be Used

Preferred 9‑month regimen: Isoniazid + rifampicin + ethambutol for the initial 2 months, followed by isoniazid + rifampicin for an additional 7 months.
Ethambutol is included only during the first 2 months. 19